BCL2L1 and small cell lung carcinoma: We found that most SCLC cell lines are dependent on BCL-XL for their survival and are highly sensitive to a BCL-XL inhibitor or our recently developed BCL-XL PROTAC DT2216 (now a clinical candidate in the phase-I trial) [16, 17].